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Previously, we identiﬁed a locus on 11p inﬂuencing obesity
in families with type 2 diabetes. Based on mouse studies,
we selected TUB as a functional candidate gene and per-
formed association studies to determine whether this con-
trols obesity. We analyzed the genotypes of 13 single
nucleotide polymorphisms (SNPs) around TUB in 492 un-
related type 2 diabetic patients with known BMI values.
One SNP (rs1528133) was found to have a signiﬁcant effect
on BMI (1.54 kg/m
2, P  0.006). This association was
conﬁrmed in a population enriched for type 2 diabetes,
using 750 individuals who were not selected for type 2
diabetes. Two SNPs in linkage disequilibrium with
rs1528133 and mapping to the 3 end of TUB, rs2272382,
and rs2272383 also affected BMI by 1.3 kg/m2 (P  0.016
and P  0.010, respectively). Combined analysis conﬁrmed
this association (P  0.005 and P  0.002, respectively).
Moreover, comparing 349 obese subjects (BMI >30 kg/m
2)
from the combined cohort with 289 normal subjects (BMI
<25 kg/m
2) revealed that the protective alleles have a
lower frequency in obese subjects (odds ratio 1.32 [95% CI
1.04–1.67], P  0.022). Altogether, data from the tubby
mouse as well as these data suggest that TUB could be an
important factor in controlling the central regulation of
body weight in humans. Diabetes 55:385–389, 2006
U
ntil recently, type 2 diabetes was considered a
disease of the elderly. Currently, worldwide, a
large proportion of newly diagnosed patients
are adolescents. The increase in the prevalence
of type 2 diabetes, as well as the rapid spreading to a
younger age at onset, is largely due to environmental
factors, including modern eating habits and reduced phys-
ical activity. Obesity is a major risk factor for type 2
diabetes, and the obesity epidemic coincides with the type
2 diabetes epidemic. Genetic studies have suggested a
common basis for both diseases. Recently, we identiﬁed a
locus on 11p15 (95% CI 4,868,745–10,676,565 bps) inﬂuenc-
ing obesity in families with type 2 diabetes (1). The TUB
gene was found to be the most relevant candidate gene
within this locus, and we hypothesized that TUB was
associated with obesity susceptibility.
TUB is the founding-member of the tubby-like proteins
and is conserved among vertebrate genomes (2). Interest-
ingly, a loss of function mutation of tub results in the tubby
mouse syndrome, which is characterized by late-onset
obesity and neurosensory deﬁcits. The tubby mouse be-
gins to diverge in weight at 12 weeks of age and
ultimately reaches twice the weight of its wild-type litter-
mates (3). Along with weight gain, tubby mouse shows
insulin resistance, although it is not overtly diabetic. The
high level of Tub expression in the hypothalamus, a brain
region that is implicated in the control of systemic energy
regulation (4), indicates that the obesity phenotype might
result from defects in neuroendocrine control of satiety or
metabolism. Recent experiments in the worm C. elegans
show that tub-1 can increase adiposity when ablated (5).
TUB is an attractive candidate gene for obesity as it is an
important and fundamental factor in metabolism and
obesity, although the role of TUB in obesity in humans has
not been established.
To investigate the role of TUB in human obesity, 13
single nucleotide polymorphisms (SNPs) around TUB
(Fig. 1A and online appendix Table 1 [available from
http://diabetes.diabetesjournals.org]) were genotyped in
492 unrelated type 2 diabetic patients from the Breda
cohort, for whom BMI values were available (Table 1).
Linear regression analysis, adjusted for age and sex,
revealed that the minor allele of SNP rs1528133 had a
marked effect on BMI (1.54 kg/m
2, P  0.006) (Fig. 1B,
Table 2). SNP rs1528133 is located 22 kb distal to TUB in
the ﬂanking gene RIC3, which has an unknown function.
SNP rs1528133 is in strong linkage disequilibrium with
SNPs in the 3 end of TUB (Fig. 1C), indicating that the
COOH-terminus of TUB may be associated with obesity. A
replication study of rs1528133 and four SNPs located in
the 3 of TUB and in linkage disequilibrium with rs1528133
(rs2272382, rs2272383, rs3750955, and rs1406095) was per-
formed in a population enriched for type 2 diabetes Dutch
cohort (RIVM) of 750 individuals (Table 1). We were able
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on BMI for the major alleles of both rs2272382 (1.28
kg/m
2, P  0.016) and rs2272383 (1.26 kg/m
2, P  0.01)
(Fig. 1B, Table 2). These two SNPs are in a strong linkage
disequilibrium with rs1528133 (D0.8 and D0.9,
respectively). Combining both cohorts (n  1,242)
strengthened the effect, as rs2272382 and rs2272383
showed even stronger association with BMI (1.12 kg/m
2,
P  0.005, 1.11 kg/m
2, P  0.002) (Fig. 1B, Table 2).
These two SNPs remained signiﬁcant in the combined
cohort after stringent Bonferroni correction for ﬁve SNPs
(Pc  0.05/5  0.01).
Comparing the 349 obese subjects from the combined
cohort (BMI 30 kg/m
2) with 289 normal subjects (BMI
25 kg/m
2) revealed that the minor allele of SNP
rs2272382 was signiﬁcantly more common in the obese
subjects (37.3%) than normal subjects (31.1%) (odds ratio
1.32 [95% CI 1.04–1.67], P  0.022), while the minor allele
of rs2272383 showed borderline signiﬁcance (1.23 [0.98–
1.55], P  0.078) (Table 3). In addition, the genotype
FIG. 1. Fine-mapping study with SNPs in and surrounding the TUB gene. A: A 130-kb region (7,993,782–8,123,921 bp) encompassing the TUB gene
and the location of the 13 SNPs used in the ﬁne mapping study. The spacing between the SNPs reﬂects the distances between them. B: The effect
of each of the SNPs on BMI (kg/m
2) for the minor allele is indicated in the upper panel and the effect on BMI (kg/m
2) for the major allele is
indicated in the lower panel, for the two cohorts (Breda and RIVM) as well as the combined cohort. *Signiﬁcant P values. P values were calculated
using the two-sided 
2 test. C: Pairwise linkage disequilibrium between the 13 SNPs, given by the D statistics computed with the genotype data
from the control cohort of 356 subjects.
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also signiﬁcantly more common in the obese subjects
(14.2%) compared with normal subjects (7.1%) (P  0.016)
(online appendix Table 2). Notably, the RIVM cohort
includes 55% type 2 diabetic subjects. In a case-control
study comparing patients with type 2 diabetes with healthy
subjects from the Breda cohort for all 13 SNPs and RIVM
cohort for all ﬁve SNPs, we found no associations (data
not shown), clearly conﬁrming the gene’s direct inﬂuence
on body weight independent of type 2 diabetes. Therefore,
the data suggests that TUB may inﬂuence BMI in general
and may not be involved in type 2 diabetes directly.
The two associated SNPs, rs2272382 and rs2272383, are
located in the highly conserved COOH-terminal domain of
tubby, which contains the DNA-binding domain and the
phosphatidylinositol-binding region. Strikingly, mutations
in the murine TUB allele and tubby-like proteins were
found to be in the same region (6,7). Comparing the
linkage disequilibrium plot (D) between these three SNPs
in the Breda case subjects and the case and control
subjects from RIVM revealed no major differences (data
not shown). Moreover, the allele frequencies were similar.
It is therefore possible that the differences between the
Breda and RIVM cohorts can be attributed to different
patterns of association between the marker allele and the
true, not yet identiﬁed, disease-associated allele. Alterna-
tively, it is possible that different alleles at the same locus
are responsible for increased risk in different populations.
It is tempting to speculate that a variation in this region
may have affected a domain important to the biological
function of tubby. However, it should be noted that the
region showing association also encompasses the RIC3
gene, which is known to be involved in neurotransmission
(8). Although we cannot formally exclude that RIC3 is
contributing to body weight, the TUB gene is a more
attractive candidate gene for body weight due to its
function.
To our knowledge, the potential contribution of TUB to
human obesity was assessed only once (9). The authors
have examined ﬁve polymorphic microsatellite markers
around TUB in 716 Pima Indians comprising 217 nuclear
families for sibpair linkage to BMI. No signiﬁcant linkages
were found in an analysis of all sibships or in an analysis
restricted to discordant sibpairs. However, this linkage
study was done in a different population and not with the
same SNPs that were used by us.
Thus, the role of tubby as an important factor in
metabolism and obesity has not been shown in humans.
Our study is the ﬁrst to provide an initial estimate of the
association of the TUB gene with a quantitative measure of
obesity. Recently, the effect of MC4R, a major gene for
obesity, on weight regulation was estimated to be 0.52
kg/m
2 (10), and since the effect of TUB on weight regula-
tion is more then twice as high (1.3 kg/m
2), this indicates
the importance of TUB’s contribution to polygenetically
regulated body weight.
Altogether, data from the tubby mouse as well as these
data suggest that tubby has a protective role in the central
regulation of body weight in humans. Mutations in TUB
can lead to increased body weight and contribute to
obesity. This discovery will reveal new molecular path-
ways in weight regulation that should lead to innovative
therapies, preventive measures, and insights into the phar-
macogenetics of such intervention strategies.
RESEARCH DESIGN AND METHODS
Subjects’ DNA, isolated from whole blood, was available from two indepen-
dent cohorts of Dutch subjects: the Breda and the RIVM cohorts (Table 1). The
Breda cohort comprised 492 individuals (267 women and 224 men). The level
of obesity in each individual was given by the BMI, deﬁned as weight in
kilograms divided by the square of height in meters. All the patients were
diagnosed according to World Health Organization criteria. There was also a
cohort of control subjects available (n  356) comprised of general random
subjects. The RIVM cohort consisted of participants in a health monitoring
project from two Dutch towns (Doetinchem and Maastricht). Subjects were
diagnosed with diabetes according to venous plasma glucose concentrations
(11.1 mmol/l for nonfasting and 7.0 mmol/l for fasting or were being
treated with tablets or insulin at the time of the health monitoring project
[1993–1997] or of a follow-up questionnaire [1998]). Control subjects were
normoglycemic (venous plasma glucose 5.5 mmol/l for nonfasting and 6.1
mmol/l for fasting participants). We excluded subjects if either of their parents
was not born in a European country. We calculated the BMI as weight (minus
1 kg for measured weight to correct for clothing) divided by the square of
height in meters (kg/m
2).
The Breda study was approved by the University Medical Center Utrecht.
The RIVM study was approved by the TNO Leiden medical ethical committee.
Written informed consent was obtained from all subjects. Experiments were
conducted according to the principles expressed in the Declaration of
Helsinki.
SNP selection and genotyping. Using linkage disequilibrium reports from
the Ensembl database (available at http://www.ensembl.org/), ﬁve SNPs
(online appendix Table 1 and Fig. 1) that “tag” the common haplotypes of a
region were selected (Tagger available at http://www.broad.mit.edu/mpg/
tagger/) in addition to eight SNPs spanning regions between the blocks in
equally spaced intervals (online appendix Table 1). Among these variants, one
SNP was positioned in the 5 upstream ﬂanking region (SNP rs2280729) and
four SNPs were positioned in the 3 downstream ﬂanking region (SNP
rs1569128, rs1528133, rs6578931, and rs10769876). All SNPs were located in
introns except for two SNPs (rs2272383 and rs3750955), which were located
in the 3 untranslated region of the gene.
Genotype analysis. SNPs were genotyped using Taqman Assay-on-Demand
(Applied Biosystems, Nieuwerkerk a/day IJssel, the Netherlands). Assays
were performed according to the manufacturer’s speciﬁcations. The geno-
types were analyzed using a TaqMan 7900HT (Applied Biosystems).
Statistical analysis. All data were analyzed using a Gaussian linear regres-
sion, including age and sex as explanatory variables in the models. The
TABLE 1
Clinical characteristics of study subjects
Trait
Breda cohort RIVM cohort
Nondiabetic
subjects Type 2 diabetic subjects
Nondiabetic
subjects Type 2 diabetic subjects
n (male/female) 356 (173/183) 492 (224/267)* 341 (197/144) 409 (259/150)
Age at study (years) 49.39  11.68* 70.3  9.9 54.78  6.63 57.1  6.1
Age at diagnosis (years) — 63.0  11.3 — 53.2  6.6†
BMI (kg/m
2) NA 27.8  4.1 26.5  3.6 29.6  4.5
n (BMI 30 kg/m
2) NA 129 48 172
n (BMI 25 kg/m
2) NA 125 111 53
Data are means  SD, unless otherwise indicated. *Not available for one subject. †Only available for 189 subjects. NA, not available.
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used for comparing the models is their ability to predict the observed data, i.e.,
models are compared directly through their minimized minus log likelihood.
When the numbers of parameters in models differ, they are penalized by
adding the number of estimated parameters, a form of the Akaike information
criterion (11). For models where the allele(s) or genotypes were found to be
signiﬁcant, a P value was computed and is presented. Differences in allele and
genotype distribution in case and control subjects were tested for signiﬁcance
using a 95% two-sided 	
2 test. Odds ratios and the CIs were calculated using
Woolf’s method with Haldane’s correction (12). For Hardy-Weinberg equilib-
rium, we compared the expected and observed genotypes in 2 
 3 tables
(online appendix Tables 3, 4, and 5).
TABLE 2
The effect of the different alleles of each of the SNPs on BMI (kg/m
2)
NCBI SNP
reference Allele
Breda cohort RIVM cohort Combined analysis
n
(492)
Effect on BMI*
(95% CI)†
P
value‡
n
(750)
Effect on BMI*
(95% CI)†
P
value‡
n
(1,242)
Effect on BMI*
(95% CI)†
P
value‡
rs2280729 Minor
(T)
479§ 0.001
(0.85 to 0.86)
Major
(C)
0.30
(0.56 to 1.17)
rs2280726 Minor
(G)
470§ 0.03
(0.75 to 0.69)
Major
(A)
0.88
(0.81 to 2.57)
rs1406095 Minor
(A)
472§ 0.16
(0.64 to 0.95)
718§ 0.03
(0.76 to 0.69)
1,190§ 0.02
(0.52 to 0.56)
Major
(G)
0.61
(0.26 to 1.49)
0.36
(1.14 to 0.42)
0.06
(0.53 to 0.65)
rs11041734 Minor
(G)
479§ 0.04
(0.67 to 0.74)
Major
(C)
0.03
(1.28 to 1.23)
rs 4385931 Minor
(C)
470§ 0.06
(1.20 to 1.32)
Major
(G)
0.42
(1.54 to 0.71)
rs2272382 Minor
(A)
467§ 0.08
(0.64 to 0.80)
726§ 0.41
(0.24 to 1.05)
1,193§ 0.35
(0.14 to 0.83)
Major
(G)
0.97
(2.13 to 0.20)
1.28
(2.32 to 0.24)
0.016 1.12
(1.91 to 0.34)
0.005¶
rs2242501 Minor
(G)
460§ 0.28
(0.43 to 0.99)
Major
(A)
0.17
(1.11 to 1.46)
rs2272383 Minor
(G)
479§ 0.41
(0.30 to 1.13)
725§ 0.01
(0.64 to 0.67)
1,204§ 0.21
(0.28 to 0.70)
Major
(A)
0.69
(1.69 to 0.31)
1.26
(2.22 to 0.30)
0.010¶ 1.11
(1.82 to 0.41)
0.002¶
rs3750955 Minor
(T)
474§ 0.07
(0.65 to 0.79)
732§ 0.20
(0.85 to 0.44)
1,206§ 0.07
(0.56 to 0.42)
Major
(C)
0.38
(1.70 to 0.93)
1.32
(0.10 to 2.74)
0.93
(1.91 to 0.05)
rs1569128 Minor
(T)
473§ 0.33
(0.39 to 1.06)
Major
(A)
0.58
(1.63 to 0.48)
rs1528133 Minor
(C)
482§ 1.54
(0.45–2.62)
0.006 719§ 0.12
(1.07 to 0.82)
1,201§ 0.54
(0.19 to 1.26)
Major
(A)
0.32
(5.80 to 5.15)
0.01
(5.37 to 5.36)
0.12
(3.62 to 3.86)
rs6578931 Minor
(T)
479§ 0.23
(0.49 to 0.95)
Major
(G)
0.28
(1.32 to 0.76)
rs10769876 Minor
(T)
470§ 0.08
(0.64 to 0.81)
Major
(C)
0.05
(1.15 to 1.25)
*All data were analyzed using a Gaussian linear regression, including age and sex as explanatory variables in the models. †The CIs were
calculated using Woolf’s method with Haldane’s correction. ‡The P values were computed with a 95% two-sided 	
2 test and are not corrected
for multiple testing. Corrected P values are 0.004 (0.05/13) and 0.01 (0.05/5) for the Breda and RIVM/combined cohorts, respectively. §Number
of subjects that were successfully genotyped. ¶P values remain signiﬁcant after stringent Bonferroni correction.
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P value
(allele)* Odds ratio (95% CI)†
rs1406095 G,A
BMI 30 357 (52.8) 319 (47.2)
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rs2272382 G,A
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2 test. †Odds ratios and the 95% CIs were calculated using Woolf’s method with
Haldane’s correction.
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